CHRS(Coherus Oncology, Inc.) · 财务报表

CHRS(Coherus Oncology, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$326.55M$211.04M$257.24M$26.39M$42.17M
毛利润$268.96M$140.96M$98.25M$17.66M$28.36M
营业利润−$263.86M−$256.88M−$203.20M−$199.65M−$181.13M
净利润−$287.10M−$291.75M−$237.89M$28.51M$168.02M
经营现金流−$37.43M−$241.12M−$174.88M−$20.44M−$138.51M
自由现金流−$38.72M−$243.16M−$175.17M——
摊薄每股收益$-3.81$-3.76$-2.53$0.25$1.43

Coherus Oncology, Inc. CHRS